

# Omar Abdel-Rahman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4845553/omar-abdel-rahman-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

302  
papers

4,526  
citations

28  
h-index

55  
g-index

320  
ext. papers

5,820  
ext. citations

3.7  
avg, IF

7.15  
L-index

#	Paper	IF	Citations
302	Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 273-285	3.6	0
301	Patterns of colorectal cancer diagnosis among younger adults in a real-world, population-based cohort. <i>Future Oncology</i> , <b>2022</b> , 18, 47-54	3.6	1
300	Cancer Burden Among Arab-World Females in 2020: Working Toward Improving Outcomes.. <i>JCO Global Oncology</i> , <b>2022</b> , 8, e2100415	3.7	0
299	Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.. <i>Current Oncology Reports</i> , <b>2022</b> , 1	6.3	0
298	Socioeconomic disparities in the prevalence of comorbid chronic conditions among Canadian adults with cancer. <i>Acta Oncologica</i> , <b>2021</b> , 1-8	3.2	
297	Outcomes of liver transplantation as an oncologic surgery for different primary liver cancers: A real-world, population-based study. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2021</b> ,	2.1	
296	Factors associated with fatal coronavirus disease 2019 infections among cancer patients in the USFDA Adverse Event Reporting System database. <i>Future Oncology</i> , <b>2021</b> , 17, 5045-5051	3.6	1
295	Racial Background and Health Behaviors Among Adults With Cancer in Canada: Results of a National Survey. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 1-9	7.3	2
294	Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 1197-1214	2.1	
293	Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the USFDA adverse event reporting system. <i>Immunotherapy</i> , <b>2021</b> , 13, 1407-1417	3.8	0
292	Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 43	2.7	4
291	A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Unknown Primary. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 876-882	5.6	1
290	Dietary Supplements Use among Adults with Cancer in the United States: A Population-Based Study. <i>Nutrition and Cancer</i> , <b>2021</b> , 73, 1856-1863	2.8	1
289	Burden of depression among Canadian adults with cancer; results from a national survey. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 667-672	2.2	1
288	Cannabis use among Canadian adults with cancer (2007-2016): results from a national survey. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 1025-1029	2.2	2
287	The impact of gender and HPV status on anal squamous cell carcinoma survival. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 2093-2109	3	1
286	Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data. <i>CMAJ Open</i> , <b>2021</b> , 9, E474-E481	2.5	1

285	Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , 33, e12971	3.8	1
284	Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study. <i>Pancreas</i> , <b>2021</b> , 50, 727-731	2.6	1
283	Hospitalizations among early-stage colon cancer patients receiving adjuvant chemotherapy: a real-world study. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 1905-1913	3	0
282	Real-world Patterns of Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation for Patients With Resected Rectal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 383-387	2.7	
281	Revisiting the AJCC staging system of adrenocortical carcinoma. <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 1	5.2	2
280	Outcomes of non-metastatic poorly differentiated gastroenteropancreatic neuroendocrine neoplasms treated with surgery: a real-world population-based study. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 941-947	3	2
279	Patient-Reported Cognitive and Functional Impairments Among Older Canadians With Cancer: a Population-Based Study. <i>Journal of Pain and Symptom Management</i> , <b>2021</b> , 61, 279-286	4.8	2
278	Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 493-499	3	2
277	Prevalence and healthcare utilization of acute respiratory infections among cancer survivors in the United States: a population-based study. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 697-704	3.8	
276	Influenza and pneumonia-attributed deaths among cancer patients in the United States; a population-based study. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 393-401	3.8	5
275	Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study. <i>Clinical Respiratory Journal</i> , <b>2021</b> , 15, 36-41	1.7	1
274	Patterns of cigarette smoking and alcohol drinking among Canadian adults with cancer in a contemporary national cohort. <i>Journal of Cancer Survivorship</i> , <b>2021</b> , 1	5.1	
273	Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 19	5.4	1
272	Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. <i>Medical Oncology</i> , <b>2021</b> , 38, 18	3.7	2
271	Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Real-world Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 158-161	2.7	2
270	Patient-related barriers to some virtual healthcare services among cancer patients in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 119-126	2.1	10
269	Patterns and association of vaccination among adults with a history of cancer in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 899-907	2.1	
268	Assessment of the AJCC staging system of pheochromocytomas/paragangliomas. <i>Endocrine</i> , <b>2021</b> , 1	4	1

267	Gender, socioeconomic status and emergency department visits among cancer survivors in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 969-977	2.1	1
266	Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study. <i>Future Oncology</i> , <b>2021</b> , 17, 3977-3986	3.6	0
265	Impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinoma—a real-world, population-based study. <i>Strahlentherapie Und Onkologie</i> , <b>2021</b> , 1	4.3	
264	Disparities in modifiable cancer risk factors among Canadian provinces, territories, and health regions. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1973-1989	2.5	
263	Outcomes of patients with nonmetastatic gastric adenocarcinoma according to perioperative treatment strategy: a real-world, population-based study. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 1143-1151	2.1	
262	Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 68-76	7.3	3
261	Inhibitors for the Treatment of Gastric Cancer: What's Their Potential?. <i>Journal of Experimental Pharmacology</i> , <b>2020</b> , 12, 349-361	3	5
260	New paradigms in the treatment of low-risk thyroid cancer. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2020</b> , 15, 251-260	4.1	1
259	Pharmacological and clinical properties of lorlatinib in the treatment of -rearranged advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1547-1554	4	4
258	A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 911-920	3	1
257	Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, 300-306	3	
256	Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1885-1891	3.6	2
255	A real-world, population-based study of the outcomes of patients with metastatic colorectal cancer to the peritoneum treated with or without cytoreductive surgery. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 719-725	3	6
254	Depression and Suicidal Ideation Among Patients With Cancer in the United States: A Population-Based Study. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, e601-e609	2.3	5
253	Death from Alzheimer's disease among cancer survivors: a population-based study. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 835-841	2.5	2
252	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , <b>2020</b> , 1, CD011313	5.2	7
251	Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1645-1650	3.6	5
250	Treatment choices and outcomes of non-metastatic hepatocellular carcinoma patients in relationship to neighborhood socioeconomic status: a population-based study. <i>International Journal of Clinical Oncology</i> , <b>2020</b> , 25, 861-866	4.2	12

249	Vitamin and herbal supplements use among patients with advanced gastrointestinal cancers included in eight clinical trials. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2089-2097	4.9	2
248	Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 415-420.e2	4.9	4
247	Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study. <i>Journal of Comparative Effectiveness Research</i> , <b>2020</b> , 9, 431-439	2.1	1
246	Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 575-581	7.3	2
245	Experiences of cancer patients with outpatient care in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , <b>2020</b> , 9, 959-967	2.1	
244	Outcomes of metastatic colorectal cancer patients in relationship to prior and concurrent antibiotics use; individual patient data analysis of three clinical trials. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1651-1656	3.6	6
243	A Real-World, Population-Based Analysis of the Outcomes of Colorectal Cancer Patients with Isolated Synchronous Liver or Lung Metastases Treated with Metastasectomy. <i>World Journal of Surgery</i> , <b>2020</b> , 44, 1604-1611	3.3	3
242	Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis. <i>International Journal of Clinical Oncology</i> , <b>2020</b> , 25, 885-891	4.2	6
241	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , <b>2020</b> , 11, CD011313	5.2	0
240	Limited surgery following neoadjuvant treatment among patients with localized rectal cancer; a population-based study. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 1221-1225	4.2	1
239	Sex-based differences in outcomes of patients with HPV-positive versus HPV-negative oropharyngeal carcinoma: a population-based study. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 813-818	3.5	2
238	Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer. <i>Journal of Comparative Effectiveness Research</i> , <b>2020</b> , 9, 1233-1241	2.1	4
237	Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel-A pooled analysis of 3 randomized studies. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 210-215	2.8	6
236	Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin: a population-based study. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 571-575	2.8	11
235	Prediagnostic BMI and thyroid cancer incidence in the PLCO trial. <i>Future Oncology</i> , <b>2019</b> , 15, 3451-3456	3.6	4
234	Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. <i>International Journal of Colorectal Disease</i> , <b>2019</b> , 34, 1741-1747	3	11
233	Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 1029-1035	3.8	9
232	Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria. <i>BMC Cancer</i> , <b>2019</b> , 19, 863	4.8	9

231	Population-based assessment of the performance of sigmoidoscopy in the detection of colorectal cancer: implications for future screening recommendations. <i>Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 10, 354-356	2.8	2
230	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1749-1768	13.4	888
229	Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	25
228	Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , <b>2019</b> , 34, 675-680	3	
227	Population-based assessment of the national comprehensive cancer network recommendations for baseline imaging of hepatocellular carcinoma. <i>Medical Oncology</i> , <b>2019</b> , 36, 26	3.7	
226	Outcomes of non-metastatic colon cancer patients in relationship to socioeconomic status: an analysis of SEER census tract-level socioeconomic database. <i>International Journal of Clinical Oncology</i> , <b>2019</b> , 24, 1582-1587	4.2	26
225	Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e837-e844	3.3	11
224	Outcomes of metastatic breast cancer patients in relationship to disease-free interval following primary treatment of localized disease; a pooled analysis of two clinical trials. <i>Breast Journal</i> , <b>2019</b> , 25, 823-828	1.2	5
223	Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World. <i>Clinical Oncology</i> , <b>2019</b> , 31, e160-e166	2.8	15
222	Assessment of the external validity of the AJCC 8 staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location?. <i>Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 10, 421-428	2.8	1
221	Chronic Postoperative Opioid Use: A Systematic Review. <i>World Journal of Surgery</i> , <b>2019</b> , 43, 2164-2174	3.3	10
220	Impact of current versus former smoking status on the outcomes of non-metastatic non-small cell lung cancer treated with upfront surgery; findings from the National Lung Screening Trial. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 585-591	3.8	2
219	Comparison of outcomes of radiotherapy-treated localized prostate cancer patients within a clinical trial setting versus real-life setting. <i>Future Oncology</i> , <b>2019</b> , 15, 1269-1277	3.6	2
218	Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2019</b> , 19, 711-715	2.2	4
217	Reply to the letter to the editor "Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials". <i>Strahlentherapie Und Onkologie</i> , <b>2019</b> , 195, 308-309	4.3	1
216	Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. <i>Immunotherapy</i> , <b>2019</b> , 11, 543-554	3.8	5
215	The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 579-584	3.8	3
214	Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study. <i>Clinical and Translational Oncology</i> , <b>2019</b> , 21, 1673-1679	3.6	

213	Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : An individual patient data analysis of three clinical trials. <i>Strahlentherapie Und Onkologie</i> , <b>2019</b> , 195, 297-305	4.3	12
212	Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. <i>Clinical and Translational Oncology</i> , <b>2019</b> , 21, 239-245	3.6	6
211	Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort. <i>Journal of Gastrointestinal Cancer</i> , <b>2019</b> , 50, 794-800	1.6	4
210	Is routine baseline brain imaging needed for all newly diagnosed non-small-cell lung cancer patients?. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 569-575	2.1	1
209	Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e385-e393	3.8	6
208	Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma. <i>Future Oncology</i> , <b>2019</b> , 15, 2267-2275	3.6	3
207	Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1767-1775	4	6
206	Impact of Timeliness of Surgical Treatment on the Outcomes of Patients with Non-metastatic Non-small Cell Lung Cancer: Findings From the PLCO Trial. <i>World Journal of Surgery</i> , <b>2019</b> , 43, 2927-2933 <sup>3</sup>	3.3	1
205	Socioeconomic predictors of suicide risk among cancer patients in the United States: A population-based study. <i>Cancer Epidemiology</i> , <b>2019</b> , 63, 101601	2.8	23
204	Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic Database. <i>Clinical Breast Cancer</i> , <b>2019</b> , 19, e717-e722 <sup>3</sup>	2.2	26
203	Asian Americans have better outcomes of non-metastatic gastric cancer compared to other United States racial groups: A secondary analysis from a randomized study. <i>World Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 11, 1151-1160	3.4	3
202	Population-based assessment of the National Comprehensive Cancer Network recommendations for baseline imaging of rectal cancer. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 1167-1172 <sup>2</sup>	2.1	0
201	ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials. <i>International Journal of Colorectal Disease</i> , <b>2019</b> , 34, 2143-2150	3	6
200	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , <b>2019</b> ,	5.2	78
199	Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma. <i>Melanoma Research</i> , <b>2019</b> , 29, 53-58	3.3	2
198	Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies. <i>Clinical and Translational Oncology</i> , <b>2019</b> , 21, 512-518	3.6	6
197	Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 110-115.e2	3.8	22
196	5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 58-63 <sup>3</sup>	3.8	25

195	Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. <i>Clinical and Translational Oncology</i> , <b>2019</b> , 21, 810-816	3.6	16
194	Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e329-e338	3.3	1
193	Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real-world, Population-based Study. <i>Clinical Breast Cancer</i> , <b>2019</b> , 19, e297-e305	3	6
192	Population-based validation of the National Comprehensive Cancer Network recommendations for baseline imaging for bladder cancer: a case for routine baseline bone scan?. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 157-163	2.1	1
191	Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma. <i>Journal of Cellular Biochemistry</i> , <b>2019</b> , 120, 3203-3214	3.7	14
190	Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 134, 56-64	7	22
189	Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e61-e68	3.8	15
188	Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e104-e112	4.3	14
187	Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 901-908	4.9	19
186	Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 903-910	2.5	12
185	Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study. <i>Medical Oncology</i> , <b>2018</b> , 35, 68	3.7	8
184	Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy. <i>Therapeutic Advances in Urology</i> , <b>2018</b> , 10, 35-42	3.2	9
183	Assessment of the external validity of the American Joint Committee on Cancer 8th staging system for anal carcinoma. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 923-929	2.5	1
182	Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma?. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2018</b> , 17, 64-69	2.1	4
181	Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin. <i>Future Oncology</i> , <b>2018</b> , 14, 471-481	3.6	8
180	Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. <i>Biomarkers in Medicine</i> , <b>2018</b> , 12, 129-139	2.3	13
179	Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994-2013). <i>Clinical Respiratory Journal</i> , <b>2018</b> , 12, 2090-2100	1.7	28
178	Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials. <i>Breast</i> , <b>2018</b> , 38, 175-180	3.6	22



177	External validation of the prostascore model in patients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study. <i>BJU International</i> , <b>2018</b> , 122, 394-400	5.6	0
176	Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review. <i>Immunotherapy</i> , <b>2018</b> , 10, 139-148	3.8	10
175	The Association Between the FTO rs9939609 Variant and Malignant Pleural Mesothelioma Risk: A Case-Control Study. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2018</b> , 22, 79-84	1.6	7
174	Comparison of three prognostic models for predicting cancer-specific survival among patients with gastrointestinal stromal tumors. <i>Future Oncology</i> , <b>2018</b> , 14, 379-389	3.6	6
173	Radical multimodality therapy for malignant pleural mesothelioma. <i>The Cochrane Library</i> , <b>2018</b> , 1, CD012605	5.0	14
172	Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 417-423	4.2	10
171	Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. <i>Molecular Cancer</i> , <b>2018</b> , 17, 54	42.1	39
170	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. <i>The Cochrane Library</i> , <b>2018</b> , 4, CD011746	5.2	33
169	Revisiting the Prognostic Heterogeneity of AJCC Stage IV Carcinomas of the Upper Urinary Tract. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e859-e865	3.3	3
168	Management of Sacrococcygeal Chordoma: A Systematic Review and Meta-analysis of Observational Studies. <i>Spine</i> , <b>2018</b> , 43, E1157-E1169	3.3	12
167	Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis. <i>Clinical Respiratory Journal</i> , <b>2018</b> , 12, 1093-1099	1.7	25
166	Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e21-e28	3.8	6
165	Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis. <i>Journal of Dermatological Treatment</i> , <b>2018</b> , 29, 176-181	2.8	15
164	Revisiting Dukes's paradigm; some node positive colon cancer patients have better prognosis than some node negative patients. <i>Clinical and Translational Oncology</i> , <b>2018</b> , 20, 794-800	3.6	6
163	Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma. <i>Hpb</i> , <b>2018</b> , 20, 41-48	3.8	22
162	Modified staging system for pulmonary carcinoids on the basis of lung cancer TNM system. <i>Clinical and Translational Oncology</i> , <b>2018</b> , 20, 670-677	3.6	7
161	Treatment at a high-volume centre is associated with improved survival among patients with non-metastatic hepatocellular carcinoma. <i>Liver International</i> , <b>2018</b> , 38, 665-675	7.9	5
160	Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. <i>Medical Oncology</i> , <b>2018</b> , 35, 123	3.7	7

159	Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study. <i>Clinical Respiratory Journal</i> , <b>2018</b> , 12, 2519-2524	1.7	5
158	Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 466-472	3.3	3
157	Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases. <i>Gastroenterology Research and Practice</i> , <b>2018</b> , 2018, 4326082	2	5
156	Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 231-238	4.4	5
155	Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. <i>BMC Cancer</i> , <b>2018</b> , 18, 688	4.8	122
154	Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. <i>Lancet Oncol</i> 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database. <i>Genitourinary and Renal Medicine</i> , <b>2018</b> , 74, 438-440	10.2	9
153	Impact of histological subtype on outcomes of renal cell carcinoma patients. <i>Journal of Drug Assessment</i> , <b>2018</b> , 7, 14-20	1.5	2
152	Impact of Regional Nodal Irradiation on the Outcomes of N1 Breast Cancer Patients Referred for Adjuvant Treatment: A Patient-Level Pooled Analysis of 2 Clinical Trials. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, 504-510	3	2
151	Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 1069-1074	4.2	2
150	Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy. <i>Breast Cancer</i> , <b>2018</b> , 25, 723-728	3.4	1
149	Challenging a dogma: five-year survival does not equal cure in all colorectal cancer patients. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 187-192	3.5	10
148	Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 65-75	3.6	5
147	Validation of the 8th AJCC staging system for gastric cancer in a population-based setting. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 525-530	4.2	8
146	Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 269-275	4.4	54
145	Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. <i>Breast Cancer</i> , <b>2018</b> , 25, 17-27	3.4	24
144	Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis. <i>Clinical Respiratory Journal</i> , <b>2018</b> , 12, 1809-1819	1.7	18
143	Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 99-107	4.2	4
142	Incorporating age into International Germ Cell Consensus Classification (IGCCC): a time to move forward?. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 101-105	3.5	3

141	Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer. <i>Clinical and Translational Oncology</i> , <b>2018</b> , 20, 550-556	3.6	9
140	External validation of the 8 American Joint Committee on Cancer staging system for gall bladder carcinoma. <i>Journal of Gastrointestinal Oncology</i> , <b>2018</b> , 9, 1084-1090	2.8	5
139	Exploring the differences between early-onset gastric cancer and traditional-onset gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2018</b> , 9, 1157-1163	2.8	11
138	Outcomes of patients in the national cancer database treated non-surgically for localized rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2018</b> , 9, 589-600	2.8	
137	Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). <i>Journal of Hepatocellular Carcinoma</i> , <b>2018</b> , 5, 109-119	5.3	9
136	Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 1231-1239	3.5	10
135	Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States. <i>Advances in Radiation Oncology</i> , <b>2018</b> , 3, 611-620	3.3	7
134	A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. <i>Cancer Medicine</i> , <b>2018</b> , 7, 6385-6392	4.8	9
133	M-bioscore: proposing a new statistical model for prognostic factors in metastatic breast cancer patients. <i>Journal of Comparative Effectiveness Research</i> , <b>2018</b> , 7, 845-854	2.1	2
132	Incidence and predictors of 1-year mortality among 9236 breast cancer patients referred for adjuvant chemotherapy. <i>Future Oncology</i> , <b>2018</b> , 14, 2335-2341	3.6	1
131	The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 2018, 4763832	2.8	4
130	Does a patient's sex predict the efficacy of cancer immunotherapy?. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 716-717	4.1	18
129	Outcomes of Surgery as Part of the Management of Metastatic Non-Small-Cell Lung Cancer: A Surveillance, Epidemiology and End Results Database Analysis. <i>Cancer Investigation</i> , <b>2018</b> , 36, 238-245	2.1	22
128	Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores. <i>Future Oncology</i> , <b>2018</b> , 14, 1469-1476	3.6	
127	Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 757-761	4.1	2
126	Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting. <i>Medical Oncology</i> , <b>2018</b> , 35, 110	3.7	5
125	Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 843-848	4.2	3
124	Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 249-258	4.2	12

123	Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e325-e335	3.3	5
122	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 387-394	3.5	89
121	External beam radiotherapy for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , <b>2017</b> , 3, CD011314	5.2	13
120	Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 695-701	4.2	31
119	Early stage hepatocellular carcinoma in the elderly: A SEER database analysis. <i>Journal of Geriatric Oncology</i> , <b>2017</b> , 8, 277-283	3.6	8
118	Radical multimodality therapy for malignant pleural mesothelioma. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	1
117	Causes of death in long-term lung cancer survivors: a SEER database analysis. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1343-1348	2.5	15
116	Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 231-236	4.4	22
115	Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 1414-1420	3.6	16
114	Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 873-878	3.5	25
113	Impact of tumor size on the outcome of patients with small renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 769-773	3.5	7
112	Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 2009-2017	2.5	10
111	Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Neurotherapeutics</i> , <b>2017</b> , 17, 725-736	4.3	15
110	Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e747-e754	3.3	10
109	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , <b>2017</b> , 29, 218-230	2.8	37
108	Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : AI propensity score matching of the SEER database. <i>Strahlentherapie Und Onkologie</i> , <b>2017</b> , 193, 276-284	4.3	9
107	Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?. <i>Immunotherapy</i> , <b>2017</b> , 9, 99-108	3.8	18
106	Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. <i>Immunotherapy</i> , <b>2017</b> , 9, 1175-1183	3.8	26

105	Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , <b>2017</b> , 8, 337-347	3.5	14
104	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <i>Immunotherapy</i> , <b>2017</b> , 9, 995-1004	3.8	10
103	Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2017</b> , 113, 128-133	5.9	9
102	Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV). <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 947-954	4.4	3
101	Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging Contexts. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e1095-e1106	3.3	8
100	Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. <i>Future Oncology</i> , <b>2017</b> , 13, 1967-1980	3.6	25
99	Impact of prior malignancies on the outcome of colorectal cancer: Revisiting clinical trial eligibility criteria. <i>Porto Biomedical Journal</i> , <b>2017</b> , 2, 212	1.1	
98	An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 1071-1076	3.5	6
97	Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies. <i>Journal of Evidence-Based Medicine</i> , <b>2017</b> , 10, 245-254	3.9	43
96	Prostascore: A Simplified Tool for Predicting Outcomes among Patients with Treatment-naïve Advanced Prostate Cancer. <i>Clinical Oncology</i> , <b>2017</b> , 29, 732-738	2.8	6
95	Clinical significance of miRNA-autophagy transcript expression in patients with hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , <b>2017</b> , 11, 641-656	2.3	2
94	Impact of liver transplantation on the risk of second malignant tumors among hepatocellular carcinoma patients. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 865-869	4.2	5
93	Dissecting the heterogeneity of stage III non-small-cell lung cancer through incorporation of grade and histology. <i>Future Oncology</i> , <b>2017</b> , 13, 2811-2821	3.6	1
92	Impact of the staging method on the prognostic utility of the 8th AJCC staging system for non-small-cell lung cancer. <i>Future Oncology</i> , <b>2017</b> , 13, 2277-2284	3.6	4
91	Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 851-856	3.5	21
90	Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 183-189	4.2	13
89	Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 364-372	3.6	10
88	Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 75-83	4.2	38

87	Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e463-e468	3.3	15
86	Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?. <i>PLoS ONE</i> , <b>2017</b> , 12, e0188450	3.7	9
85	Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2017</b> , 17, 1228-1233	2.2	6
84	Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 1872-1880	5.6	89
83	Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 97, 65-71	7	25
82	Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. <i>Melanoma Management</i> , <b>2016</b> , 3, 231-243	2.1	4
81	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , <b>2016</b> , 28, e127-38	2.8	30
80	Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 869-77	4.2	22
79	Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. <i>Future Oncology</i> , <b>2016</b> , 12, 413-25	3.6	94
78	Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. <i>Clinical and Translational Oncology</i> , <b>2016</b> , 18, 848-58	3.6	18
77	Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. <i>Future Oncology</i> , <b>2016</b> , 12, 25-30	3.6	4
76	Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 911-23	4.1	7
75	Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting. <i>Future Oncology</i> , <b>2016</b> , 12, 871-9	3.6	2
74	Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2016</b> , 10, 265-74	4.9	12
73	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 101, 75-85	7	84
72	S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , <b>2016</b> , 12, 701-13	3.6	4
71	S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 437-48	4.1	
70	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2016</b> , 10, 183-93	4.9	90

69	Combined Chemohormonal Strategy in Hormone-Sensitive Prostate Cancer: A Pooled Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 203-9	3.3	4
68	S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 5-20	4.1	8
67	Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. <i>Expert Review of Respiratory Medicine</i> , <b>2016</b> , 10, 223-34	3.8	3
66	Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 5896-908	5.6	7
65	Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer?. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E794-5	2.6	
64	Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. <i>Immunotherapy</i> , <b>2016</b> , 8, 1383-1391	3.8	14
63	Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 108, 1-12	7	18
62	Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 885-91	3.5	8
61	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , <b>2016</b> , 8, 665-74	3.8	30
60	Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 265-77	4.5	30
59	Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 102, 89-100	7	9
58	Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , <b>2016</b> , 8, 396-406	5.4	13
57	Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis. <i>Future Oncology</i> , <b>2016</b> , 12, 2163-72	3.6	4
56	PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. <i>Immunotherapy</i> , <b>2016</b> , 8, 1081-9	3.8	24
55	Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 94, 45-54	7	11
54	Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 829-37	3.5	13
53	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 847-58	3.5	11
52	Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review. <i>Future Oncology</i> , <b>2015</b> , 11, 1829-43	3.6	10

51	Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 165-82	3.5	9
50	Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 465-75	3.5	12
49	Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. <i>Medical Oncology</i> , <b>2015</b> , 32, 431	3.7	10
48	Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data. <i>Tumor Biology</i> , <b>2015</b> , 36, 467-78	2.9	10
47	Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature. <i>Future Oncology</i> , <b>2015</b> , 11, 1275-90	3.6	16
46	Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 1507-18	4.1	40
45	Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 1433-45	4.2	12
44	Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. <i>Expert Review of Respiratory Medicine</i> , <b>2015</b> , 9, 533-49	3.8	8
43	Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis. <i>Future Oncology</i> , <b>2015</b> , 11, 2949-61	3.6	5
42	Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 235-45	3.5	6
41	Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 975-86	2.5	10
40	Targeting FGF receptors in colorectal cancer: from bench side to bed side. <i>Future Oncology</i> , <b>2015</b> , 11, 1373-9	3.6	5
39	Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 1255-70	4.3	5
38	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 1495-506	4.1	6
37	Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. <i>Future Oncology</i> , <b>2015</b> , 11, 2471-84	3.6	59
36	Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. <i>Future Oncology</i> , <b>2015</b> , 11, 3307-19	3.6	8
35	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , <b>2015</b> , 7, 1213-27	3.8	71
34	Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. <i>Future Oncology</i> , <b>2015</b> , 11, 79-90	3.6	12



33	Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 129-41	3.5	18
32	Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 18-27	7	44
31	Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 295-305	4.9	25
30	Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations. <i>Tumor Biology</i> , <b>2015</b> , 36, 21-31	2.9	3
29	Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers. <i>Therapeutics and Clinical Risk Management</i> , <b>2015</b> , 11, 1123-32	2.9	5
28	Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. <i>Future Oncology</i> , <b>2015</b> , 11, 1109-22 <sup>3.6</sup>	3.6	16
27	Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. <i>Arab Journal of Gastroenterology</i> , <b>2015</b> , 16, 40-5	1.7	3
26	Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 477-86	3.5	3
25	Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis. <i>Journal of Global Oncology</i> , <b>2015</b> , 1, 73-82	2.6	20
24	New hope on the horizon for patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , <b>2015</b> , 4, 229-239	2.3	3
23	Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials. <i>Tumor Biology</i> , <b>2015</b> , 36, 1367-74	2.9	15
22	Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 94, 238-50	7	9
21	Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 127-35	7	48
20	Hepatocellular carcinoma (HCC); aetiological considerations. <i>Advances in Modern Oncology Research</i> , <b>2015</b> , 1, 18		4
19	Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. <i>Tumor Biology</i> , <b>2014</b> , 35, 10615-25	2.9	17
18	Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 92, 194-207	7	45
17	RAF signaling in neuroendocrine neoplasms: from bench to bedside. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 974-9	14.4	16
16	Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 1443-67	4.1	5

15	Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 91, 1-8	7	48
14	Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 1063-73	3.5	22
13	Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma. <i>Current Oncology Reports</i> , <b>2014</b> , 16, 394	6.3	14
12	Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 1229-42	3.5	6
11	Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 751-60	3.5	17
10	Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 1529-36	3.5	13
9	Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. <i>Future Oncology</i> , <b>2014</b> , 10, 1981-92	3.6	27
8	Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 999-1008 <sup>4.1</sup>		11
7	Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis. <i>Chemotherapy</i> , <b>2014</b> , 60, 325-33	3.2	16
6	Sphenoidal esthesioneuroblastoma treated with sequential chemo radiotherapy: a case report and review of the literature. <i>Journal of Cancer Research and Therapeutics</i> , <b>2014</b> , 10, 1101-3	1.2	0
5	Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, R485-93	5.7	18
4	Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. <i>Journal of the Egyptian National Cancer Institute</i> , <b>2014</b> , 26, 9-13	1.9	16
3	Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. <i>Medical Oncology</i> , <b>2013</b> , 30, 655	3.7	39
2	Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. <i>Journal of the Egyptian National Cancer Institute</i> , <b>2013</b> , 25, 165-71	1.9	37
1	Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 3389-96	4	57